• Search History (Register)
  • MeSH Browser
    • Afrikaans
      Albanian
      Arabic
      Armenian
      Basque
      Bengali
      Bulgarian
      Catalan
      Cambodian
      Chinese (Mandarin)
      Chinese (Cantonese)
      Croatian
      Czech
      Danish
      Dutch
      English
      Estonian
      Fiji
      Finnish
      French
      Georgian
      German
      Greek
      Gujarati
      Hebrew
      Hindi
      Hungarian
      Icelandic
      Indonesian
      Irish
      Italian
      Japanese
      Javanese
      Korean
      Latin
      Latvian
      Lithuanian
      Macedonian
      Malay
      Malayalam
      Maltese
      Maori
      Marathi
      Mongolian
      Nepali
      Norwegian
      Persian
      Polish
      Portuguese
      Punjabi
      Quechua
      Romanian
      Russian
      Samoan
      Serbian
      Slovak
      Slovenian
      Spanish
      Swahili
      Swedish
      Tamil
      Tatar
      Telugu
      Thai
      Tibetan
      Tonga
      Turkish
      Ukrainian
      Urdu
      Uzbek
      Vietnamese
      Welsh
      Xhosa
      Apply
    • Adelaide Health Technology Assessment
      Agence d'évaluation des technologies et des modes d'intervention en santé
      Agencia de Evaluacion de Tecnologias Sanitarias
      Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)
      Agencia de Qualitat i Avaluacio Sanitries de Catalunya
      Agency for Care Effectiveness (ACE)
      Agency for Health Technology Assessment and Tariff System
      Agency for Healthcare Research and Quality
      Agenzia Sanitaria e Sociale Regionale (Regional Agency for Health and Social Care)
      All Wales Medicines Strategy Group
      Andalusian Health Technology Assessment Area
      Australian Health Technology Advisory Committee
      Australian Safety and Efficacy Register of New Interventional Procedures-Surgical
      Austrian Institute for Health Technology Assessment
      Basque Office for Health Technology Assessment
      Belgian Health Care Knowledge Centre
      BlueCross BlueShield Association
      British Columbia Office of Health Technology Assessment
      Canadian Agency for Drugs and Technologies in Health
      Canadian Coordinating Office for Health Technology Assessment
      Canadian Task Force on Preventive Health Care
      Canary Health Service
      Cellule Innovation of the AP-HP
      Center for Drug Evaluation
      Center for Medical Technology Assessment
      Center for Outcomes Research and Economic Evaluation for Health
      Centre for Clinical Effectiveness
      Centre for Reviews and Dissemination
      Centre for Technology Assessment at the Swiss Science and Technology Council
      Centre Hospitalier de l'Universite de Montreal
      Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale
      Committee for New Health Technology Assessment
      Conseil d'Evaluation des Technologies de la Santé du Québec
      Coordenação-Geral de Fomento à Pesquisa e Avaliação de Tecnologias em Saúde, Departamento de Ciência e Tecnologia
      Danish Centre for Evaluation and Health Technology Assessment
      Danish Institute for Health Services Research
      ECRI Institute
      European Network for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore
      German Agency for HTA at the German Institute for Medical Documentation and Information
      Gesundheit Osterreich GmbH
      Hannover Medical School, Medizinische Hochschule Hannover
      Haute Autorité de Santé
      HAYES, Inc.
      Health Council of the Netherlands Gezondheidsraad
      Health Information and Quality Authority (HIQA)
      Health Intervention and Technology Assessment Program
      Health Quality Ontario
      Health Sciences Institute in Aragon (IACS)
      Health Services Assessment Collaboration
      Health Services Utilization and Research Commission
      Health Technology Advisory Committee
      Health Technology and Policy Unit
      Health Technology Assessment Section, Ministry of Health Malaysia
      Health Technology Board for Scotland
      Health Technology Reference Group
      Health Technology Wales
      HTA Region Stockholm
      HTA South
      HTA Unit, University of Calgary
      Institut national d'excellence en sante et en services sociaux
      Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval)
      Institute for Clinical and Economic Review
      Institute for Clinical Effectiveness and Health Policy
      Institute for Clinical Evaluative Sciences
      Institute for Clinical Systems Improvement
      Institute for Quality and Efficiency in Health Care (IQWiG)
      Institute of Applied Health Sciences
      Institute of Health Economics
      Institute of Health Economics
      Institute of Health Technology Assessment and Research (IETSI)
      Institute of Technology Assessment
      Israel Center for Technology Assessment in Health Care
      L'Agence Nationale d'Accreditation d'Evaluation en Santé
      Ludwig Boltzmann Institute for Health Technology Assessment
      Malaysian Health Technology Assessment
      Malaysian Health Technology Assessment Unit
      Medical Advisory Secretariat
      Medical Services Advisory Committee
      Monash Business School, Monash University (MBS)
      National Authority for Assessment and Accreditation in Healthcare (INEAS)
      National Committee for Technology Incorporation (CONITEC)
      National Evidence-based healthcare Collaborating Agency
      National Institute for Clinical Excellence
      National Institute for Health and Care Excellence
      New Zealand Health Technology Assessment
      New Zealand National Health Committee
      NIHR Health and Social Care Delivery Program
      NIHR Health Services and Delivery Research programme
      NIHR Health Technology Assessment programme
      NIHR Horizon Scanning Centre
      NIHR Public Health Research programme
      Norwegian Institute of Public Health
      Norwegian Institute of Public Health
      Norwegian Medical Products Agency
      Ontario Health
      Penn Medicine Center for Evidence-based Practice
      Quality Improvement Scotland
      Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)
      Scottish Health Purchasing Information Centre
      Scottish Health Technologies Group
      Scottish Medicines Consortium (SMC)
      State Health Care Accreditation Agency under the Ministry of Health of the Republic of Lithuania
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swiss Federal Office of Public Health (FOPH)
      Technology Assessment at SickKids
      Technology Assessment Unit of the McGill University Health Centre (MUHC)
      The Danish Health Technology Council
      The Federal Joint Committee
      The HTA Center of the Stockholm County Council/Gotland
      The Italian National Agency for Regional Health Services (Agenas)
      The National Health Care Institute (ZIN, Zorginstituut Nederland)
      The National Health Care Institute (Zorginstituut Nederland)
      The Netherlands Organisation for Health Research and Development
      The Regional Health Technology Assessment Centre
      TNO
      U. S. Congress. Office of Technology Assessment
      Unidad de Evaluacion de Tecnologias Sanitarias
      Unidad de Tecnologias de Salud
      Unit of Health Economics and Technology Assessment in Health Care
      University HealthSystem Consortium
      University of York
      VA Technology Assessment Program
      Washington Singer Press
      Washington State Department of Labor and Industries (WSDLI)
      Wessex Institute for Health Research and Development
      West Midlands Health Technology Assessment Collaboration
      WorkSafeBC
      Apply
    • Afghanistan
      Albania
      Algeria
      Andorra
      Antigua and Barbuda
      Argentina
      Armenia
      Australia
      Austria
      Azerbaijan
      Bahamas
      Bahrain
      Bangladesh
      Barbados
      Belarus
      Belgium
      Belize
      Benin
      Bhutan
      Bolivia
      Bosnia and Herzegovina
      Botswana
      Brazil
      Brunei
      Bulgaria
      Burkina Faso
      Burundi
      Cambodia
      Cameroon
      Canada
      Cape Verde
      Central African Republic
      Chad
      Chile
      China
      Colombia
      Comoros
      Congo
      Costa Rica
      Cote dIvoire
      Croatia
      Cuba
      Cyprus
      Czech Republic
      Denmark
      Djibouti
      Dominica
      Dominican Republic
      East Timor
      Ecuador
      Egypt
      El Salvador
      Equatorial Guinea
      Eritrea
      Estonia
      Ethiopia
      Fiji
      Finland
      France
      Gabon
      Gambia
      Georgia
      Germany
      Ghana
      Greece
      Grenada
      Guatemala
      Guinea
      Guinea-Bissau
      Guyana
      Haiti
      Honduras
      Hong Kong
      Hungary
      Iceland
      India
      Indonesia
      Iran
      Iraq
      Ireland
      Israel
      Italy
      Jamaica
      Japan
      Jordan
      Kazakhstan
      Kenya
      Kiribati
      North Korea
      South Korea
      Kuwait
      Kyrgyzstan
      Laos
      Latvia
      Lebanon
      Lesotho
      Liberia
      Libya
      Liechtenstein
      Lithuania
      Luxembourg
      Macedonia
      Madagascar
      Malawi
      Malaysia
      Maldives
      Mali
      Malta
      Marshall Islands
      Mauritania
      Mauritius
      Mexico
      Micronesia
      Moldova
      Monaco
      Mongolia
      Montenegro
      Morocco
      Mozambique
      Myanmar
      Namibia
      Nauru
      Nepal
      Netherlands
      New Zealand
      Nicaragua
      Niger
      Nigeria
      Norway
      Oman
      Pakistan
      Palau
      Panama
      Papua New Guinea
      Paraguay
      Peru
      Philippines
      Poland
      Portugal
      Puerto Rico
      Qatar
      Romania
      Russia
      Rwanda
      Saint Kitts and Nevis
      Saint Lucia
      Saint Vincent and the Grenadines
      Samoa
      San Marino
      Sao Tome and Principe
      Saudi Arabia
      Senegal
      Serbia and Montenegro
      Seychelles
      Sierra Leone
      Singapore
      Slovakia
      Slovenia
      Solomon Islands
      Somalia
      South Africa
      Spain
      Sri Lanka
      Sudan
      Suriname
      Swaziland
      Sweden
      Switzerland
      Syria
      Taiwan
      Tajikistan
      Tanzania
      Thailand
      Togo
      Tonga
      Trinidad and Tobago
      Tunisia
      Turkey
      Turkmenistan
      Tuvalu
      Uganda
      Ukraine
      United Arab Emirates
      United Kingdom
      United States
      Uruguay
      Uzbekistan
      Vanuatu
      Vatican City
      Venezuela
      Vietnam
      Yemen
      Zambia
      Zimbabwe
      Apply
Sort by Relevance
CSV RIS
Search Results [15895 Hits] Selected Records [0 Hits] [Clear]
Year Source Title
2019 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dapagliflozin (type 2 diabetes mellitus) - Benefit assessment according to §35a Social Code Book V]
2019 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dapagliflozin (type 1 diabetes mellitus) - Addendum to Commission A19-37]
2019 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Data-supported timely management in cooperation with a centre for telemedicine for patients with advanced cardiac failure - rapid report]
2019 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Relationship between volume of services and quality of treatment outcome for lung cancer - rapid report]
2019 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Olaparib (breast cancer) - Benefit assessment according to §35a Social Code Book V]
2019 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Olaparib (ovarian cancer) - Benefit assessment according to §35a Social Code Book V]
2019 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Fremanezumab (migraine) - Addendum to Commission A19-44]
2019 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Risankizumab (plaque psoriasis) - Second Addendum to Commission A19-41]
2019 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Turoctocog alfa pegol - Benefit assessment according to §35a Social Code Book V]
2019 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dolutegravir/lamivudine (HIV infection) - Benefit assessment according to §35a Social Code Book V]
2019 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Cemiplimab - Benefit assessment according to §35a Social Code Book V]
2019 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ravulizumab - Benefit assessment according to §35a Social Code Book V]
2019 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Risankizumab (plaque psoriasis) - Addendum to Commission A19-41]
2019 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Volanesorsen (familial chylomicronaemia syndrome) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2019 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pomalidomide (multiple myeloma) - Addendum to Commission A19-50]
2019 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ivacaftor (cystic fibrosis, 18 years and older, with R117H mutation) - Benefit assessment according to §35a Social Code Book V]
2019 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ivacaftor (cystic fibrosis, 2 years and older, with gating mutations) - Benefit assessment according to §35a Social Code Book V]
2019 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ramucirumab (hepatocellular carcinoma) - Benefit assessment according to §35a Social Code Book V]
2019 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ivacaftor (cystic fibrosis, 6 years and older, with G551D mutation) - Benefit assessment according to §35a Social Code Book V]
2019 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ivacaftor (combination with ivacaftor/tezacaftor, cystic fibrosis, 12 years and older, with F508del mutation, heterozygous) - Benefit assessment according to §35a Social Code Book V]
2019 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ivacaftor (cystic fibrosis, 6 years and older, with gating mutations) - Benefit assessment according to §35a Social Code Book V]
2019 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ivacaftor (cystic fibrosis, from 12 to < 24 months, with gating mutations) - Benefit assessment according to §35a Social Code Book V]
2019 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ivacaftor (combination with ivacaftor/tezacaftor, cystic fibrosis, 12 years and older, with F508del mutation, homozygous) - Benefit assessment according to §35a Social Code Book V]
2019 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dupilumab (asthma) - Benefit assessment according to §35a Social Code Book V]
2019 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ibrutinib (new therapeutic indication, Waldenstroem macroglobulinaemia) - Benefit assessment according to §35a Social Code Book V]
2019 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dupilumab (atopic dermatitis in adolescents) - Benefit assessment according to §35a Social Code Book V]
2019 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Andexanet alfa (acute major bleeding) - Benefit assessment according to §35a Social Code Book V]
2019 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dapagliflozin (type 2 diabetes mellitus) - Addendum to Commission A19-53]
2019 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dapagliflozin/metformin (type 2 diabetes mellitus) - Addendum to Commission A19-52]
2019 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Olaparib (breast cancer) - Addendum to Commission A19-57]
2019 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Burosumab (X-linked hypophosphataemia) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V (expiry of the decision)]
2019 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Elotuzumab (multiple myeloma) - Benefit assessment according to §35a Social Code Book V]
2019 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Atezolizumab (NSCLC, combination chemotherapy with paclitaxel) - Benefit assessment according to §35a Social Code Book V]
2019 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Atezolizumab (breast cancer) - Benefit assessment according to §35a Social Code Book V]
2019 Health Information and Quality Authority (HIQA) Health technology assessment of C-reactive protein point-of-care testing to guide antibiotic prescribing for acute respiratory tract infections in primary care settings
2019 Health Information and Quality Authority (HIQA) Health technology assessment of a PrEP programme for populations at substantial risk of sexual acquisition of HIV
2019 Health Information and Quality Authority (HIQA) Health technology assessment of transcatheter aortic valve implantation (TAVI) in patients with severe symptomatic aortic stenosis at low and intermediate risk of surgical complications
2019 Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Rehabilitation for adults with traumatic brain injury]
2019 Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Risk and needs assessment regarding reoffending in adolescents]
2019 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Benefit assessment of biotechnologically produced drugs for the treatment of rheumatoid arthritis]
2019 Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Partial breast radiotherapy for patients with early breast cancer after breast conservation surgery
2019 Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Volume-outcome relationships: pancreaticoduodenectomy (Whipple procedure). Final report
2019 Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Endoscopic sleeve gastroplasty (ESG) for the treatment of patients with Class I and Class II obesity with comorbidities who have failed first-line treatments
2019 Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Review of immunoglobulin use for chronic inflammatory demyelinating polyneuropathy
2019 Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Endoscopic sleeve gastroplasty (ESG) for the treatment of patients with Class I and II obesity who have failed first-line treatments
2019 Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Paediatric deep brain stimulation
2019 Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Minimally invasive pancreaticoduodenectomy: the evidence
2019 Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Chondroitin sulfate in osteoarthritis
2019 Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Human dermal allograft for massive rotator cuff tears
2019 Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Clinical practice visits: a rapid review
2019 Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Charity and corporate boxing: harm mitigation
2019 Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Transmural fixation of aortic endograft adjunct to endovascular aneurysm repair using helical anchors
2019 Agency for Healthcare Research and Quality (AHRQ) Achieving health equity in preventive services
2019 Agency for Healthcare Research and Quality (AHRQ) Addressing social isolation to improve the health of older adults: a rapid review
2019 Agency for Healthcare Research and Quality (AHRQ) Adverse effects of pharmacological treatments of major depression in older adults
2019 Agency for Healthcare Research and Quality (AHRQ) Antipsychotics for the prevention and treatment of delirium
2019 Agency for Healthcare Research and Quality (AHRQ) Comparative effectiveness of analgesics to reduce acute pain in the prehospital setting
2019 Agency for Healthcare Research and Quality (AHRQ) Long-term drug therapy and drug holidays for osteoporosis fracture prevention: a systematic review
2019 Agency for Healthcare Research and Quality (AHRQ) Management of infertility
2019 Agency for Healthcare Research and Quality (AHRQ) Pharmacologic and nonpharmacologic therapies in adult patients with exacerbation of COPD
2019 Agency for Healthcare Research and Quality (AHRQ) Telehealth for acute and chronic care consultations
2019 Agency for Healthcare Research and Quality (AHRQ) Treatment for acute pain: an evidence map
2019 Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval) [Use of incentive spirometry for the prevention of pulmonary complications following surgery]
2019 Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval) [Measurement of gastric residual volume during enteral feeding in patients hospitalized in the intensive care unit]
2019 Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval) [Induction immunosuppressive therapy in patients undergoing heart transplantation]
2019 Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval) [Evaluation of the effectiveness and cost effectiveness of cardiac rehabilitation programs]
2019 Canary Health Service [PACS system and its possible application in the management of NO-DICOM clinical objects]
2019 Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Evaluation of strategies to prevent urinary tract infections related to urethral catheters in critically ill patients in intensive care units]
2019 Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Evidence on the personalization of population-based breast cancer screening]
2019 Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Cerenkov lluminescence imaging system for intraoperative assessment of surgical margins in breast, prostate, and gastrointestinal cancer]
2019 Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [MALDI-TOF mass spectrometry technology in the diagnosis of antibiotic resistance]
2019 Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Economic, organization and safety impact of drug robotic dispensing in Spanish hospitals]
2019 Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Powder bed fusion manufacturing of titanium for customized bone replacements in craneomaxillofacial reconstruction]
2019 The Regional Health Technology Assessment Centre (HTA-centrum) Efficacy of sleep deprivation in patients with depression including bipolar depression
2019 The Regional Health Technology Assessment Centre (HTA-centrum) Effectiveness and safety of microsurgical testicular sperm extraction in infertile men with non-obstructive azoospermia
2019 The Regional Health Technology Assessment Centre (HTA-centrum) Gene expression profiles to guide adjuvant chemotherapy in luminal, HER2-negative breast cancer
2019 The Regional Health Technology Assessment Centre (HTA-centrum) Impact of postmastectomy radiotherapy on complications and results of immediate breast reconstruction
2019 The Regional Health Technology Assessment Centre (HTA-centrum) EEG-based neurofeedback as treatment for post-traumatic stress disorder
2019 The Regional Health Technology Assessment Centre (HTA-centrum) Trabecular bone pattern assessment in dental radiographs for prediction of bone fracture risk
2019 National Institute for Health and Care Excellence (NICE) Regorafenib for previously treated advanced hepatocellular carcinoma. NICE technology appraisal guidance 555
2019 National Institute for Health and Care Excellence (NICE) Darvadstrocel for treating complex perianal fistulas in Crohn's disease. NICE technology appraisal guidance 556
2019 National Institute for Health and Care Excellence (NICE) Bevacizumab with carboplatin, gemcitabine and paclitaxel for treating the first recurrence of platinum-sensitive advanced ovarian cancer (terminated appraisal). NICE technology appraisal guidance 560
2019 National Institute for Health and Care Excellence (NICE) Venetoclax with rituximab for previously treated chronic lymphocytic leukaemia. NICE technology appraisal guidance 561
2019 National Institute for Health and Care Excellence (NICE) Encorafenib with binimetinib for unresectable or metastatic BRAF V600 mutation-positive melanoma. NICE technology appraisal guidance 562
2019 National Institute for Health and Care Excellence (NICE) Abemaciclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer. NICE technology appraisal guidance 563
2019 National Institute for Health and Care Excellence (NICE) Benralizumab for treating severe eosinophilic asthma. NICE technology appraisal guidance 565
2019 National Institute for Health and Care Excellence (NICE) Cochlear implants for children and adults with severe to profound deafness. NICE technology appraisal guidance 566
2019 National Institute for Health and Care Excellence (NICE) Tisagenlecleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies. NICE technology appraisal guidance 567
2019 National Institute for Health and Care Excellence (NICE) Abatacept for treating psoriatic arthritis after DMARDs (terminated appraisal). NICE technology appraisal guidance 568
2019 National Institute for Health and Care Excellence (NICE) Pertuzumab for adjuvant treatment of HER2-positive early stage breast cancer. NICE technology appraisal guidance 569
2019 National Institute for Health and Care Excellence (NICE) Pembrolizumab for treating recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy (terminated appraisal). NICE technology appraisal guidance 570
2019 National Institute for Health and Care Excellence (NICE) Brigatinib for treating ALK-positive advanced non-small-cell lung cancer after crizotinib. NICE technology appraisal guidance 571
2019 National Institute for Health and Care Excellence (NICE) Ertugliflozin as monotherapy or with metformin for treating type 2 diabetes. NICE technology appraisal guidance 572
2019 National Institute for Health and Care Excellence (NICE) Certolizumab pegol for treating moderate to severe plaque psoriasis. NICE technology appraisal guidance 574
2019 National Institute for Health and Care Excellence (NICE) Tildrakizumab for treating moderate to severe plaque psoriasis. NICE technology appraisal guidance 575
2019 National Institute for Health and Care Excellence (NICE) Bosutinib for untreated chronic myeloid leukaemia (terminated appraisal). NICE technology appraisal guidance 576
2019 National Institute for Health and Care Excellence (NICE) Brentuximab vedotin for treating CD30-positive cutaneous T-cell lymphoma. NICE technology appraisal guidance 577
2019 National Institute for Health and Care Excellence (NICE) Enzalutamide for hormone-relapsed non-metastatic prostate cancer. NICE technology appraisal guidance 580
2019 National Institute for Health and Care Excellence (NICE) Ertugliflozin with metformin and a dipeptidyl peptidase-4 inhibitor for treating type 2 diabetes. NICE technology appraisal guidance 583
2019 National Institute for Health and Care Excellence (NICE) Atezolizumab in combination for treating metastatic non-squamous non-small-cell lung cancer. NICE technology appraisal guidance 584